280 related articles for article (PubMed ID: 26241347)
21. Frequent PTEN/MMAC mutations in endometrioid but not serous or mucinous epithelial ovarian tumors.
Obata K; Morland SJ; Watson RH; Hitchcock A; Chenevix-Trench G; Thomas EJ; Campbell IG
Cancer Res; 1998 May; 58(10):2095-7. PubMed ID: 9605750
[TBL] [Abstract][Full Text] [Related]
22. Morphologic and Molecular Characteristics of Mixed Epithelial Ovarian Cancers.
Mackenzie R; Talhouk A; Eshragh S; Lau S; Cheung D; Chow C; Le N; Cook LS; Wilkinson N; McDermott J; Singh N; Kommoss F; Pfisterer J; Huntsman DG; Köbel M; Kommoss S; Gilks CB; Anglesio MS
Am J Surg Pathol; 2015 Nov; 39(11):1548-57. PubMed ID: 26099008
[TBL] [Abstract][Full Text] [Related]
23. Prognostic impact of concomitant p53 and PTEN on outcome in early stage (FIGO I-II) epithelial ovarian cancer.
Skírnisdóttir I; Seidal T
Int J Gynecol Cancer; 2011 Aug; 21(6):1024-31. PubMed ID: 21792012
[TBL] [Abstract][Full Text] [Related]
24. An in vivo model for the study of ovarian cancer and the persistence of characteristic mutations in xenografts.
Li Y; Gu YJ; Liu CN; Yue TF
Eur J Gynaecol Oncol; 2014; 35(4):387-92. PubMed ID: 25118479
[TBL] [Abstract][Full Text] [Related]
25. A universal genetic testing initiative for patients with high-grade, non-mucinous epithelial ovarian cancer and the implications for cancer treatment.
Bednar EM; Oakley HD; Sun CC; Burke CC; Munsell MF; Westin SN; Lu KH
Gynecol Oncol; 2017 Aug; 146(2):399-404. PubMed ID: 28610746
[TBL] [Abstract][Full Text] [Related]
26. Low-grade serous carcinoma: molecular features and contemporary treatment strategies.
Angarita AM; Cholakian D; Fader AN
Expert Rev Anticancer Ther; 2015; 15(8):893-9. PubMed ID: 26040191
[TBL] [Abstract][Full Text] [Related]
27. Aberrant Expression of Anaplastic Lymphoma Kinase in Ovarian Carcinoma Independent of Gene Rearrangement.
Tang S; Yang F; Du X; Lu Y; Zhang L; Zhou X
Int J Gynecol Pathol; 2016 Jul; 35(4):337-47. PubMed ID: 27271776
[TBL] [Abstract][Full Text] [Related]
28. Inhibition of nuclear factor-kappa B enhances the tumor growth of ovarian cancer cell line derived from a low-grade papillary serous carcinoma in p53-independent pathway.
Xiao X; Yang G; Bai P; Gui S; Nyuyen TM; Mercado-Uribe I; Yang M; Zou J; Li Q; Xiao J; Chang B; Liu G; Wang H; Liu J
BMC Cancer; 2016 Aug; 16():582. PubMed ID: 27484466
[TBL] [Abstract][Full Text] [Related]
29. Expression of BRAF V600E mutant protein in epithelial ovarian tumors.
Preusser M; Capper D; Berghoff AS; Horvat R; Wrba F; Schindl M; Schoppmann SF; von Deimling A; Birner P
Appl Immunohistochem Mol Morphol; 2013 Mar; 21(2):159-64. PubMed ID: 22820660
[TBL] [Abstract][Full Text] [Related]
30. The efficacy of tamoxifen in patients with advanced epithelial ovarian cancer.
Karagol H; Saip P; Uygun K; Caloglu M; Eralp Y; Tas F; Aydiner A; Topuz E
Med Oncol; 2007; 24(1):39-43. PubMed ID: 17673810
[TBL] [Abstract][Full Text] [Related]
31. [The immunohistochemical features of ovarian serous adenocarcinoma cells, which determine a disease course and survival rates in patients].
Pozharissky KM; Raskin GA; Vinokurov VL; Yurkova LE; Mukhina MS
Arkh Patol; 2015; 77(1):38-40. PubMed ID: 25868367
[TBL] [Abstract][Full Text] [Related]
32. Biology of epithelial ovarian cancer: implications for screening women at high genetic risk.
Hogg R; Friedlander M
J Clin Oncol; 2004 Apr; 22(7):1315-27. PubMed ID: 15051780
[TBL] [Abstract][Full Text] [Related]
33. Cancerous ovarian stem cells: obscure targets for therapy but relevant to chemoresistance.
Ahmed N; Abubaker K; Findlay J; Quinn M
J Cell Biochem; 2013 Jan; 114(1):21-34. PubMed ID: 22887554
[TBL] [Abstract][Full Text] [Related]
34. Sox10 expression in ovarian epithelial tumors is associated with poor overall survival.
Kwon AY; Heo I; Lee HJ; Kim G; Kang H; Heo JH; Kim TH; An HJ
Virchows Arch; 2016 May; 468(5):597-605. PubMed ID: 26951260
[TBL] [Abstract][Full Text] [Related]
35. Targeted deep sequencing of mucinous ovarian tumors reveals multiple overlapping RAS-pathway activating mutations in borderline and cancerous neoplasms.
Mackenzie R; Kommoss S; Winterhoff BJ; Kipp BR; Garcia JJ; Voss J; Halling K; Karnezis A; Senz J; Yang W; Prigge ES; Reuschenbach M; Doeberitz MV; Gilks BC; Huntsman DG; Bakkum-Gamez J; McAlpine JN; Anglesio MS
BMC Cancer; 2015 May; 15():415. PubMed ID: 25986173
[TBL] [Abstract][Full Text] [Related]
36. Keratin 5 overexpression is associated with serous ovarian cancer recurrence and chemotherapy resistance.
Ricciardelli C; Lokman NA; Pyragius CE; Ween MP; Macpherson AM; Ruszkiewicz A; Hoffmann P; Oehler MK
Oncotarget; 2017 Mar; 8(11):17819-17832. PubMed ID: 28147318
[TBL] [Abstract][Full Text] [Related]
37. Type-specific cell line models for type-specific ovarian cancer research.
Anglesio MS; Wiegand KC; Melnyk N; Chow C; Salamanca C; Prentice LM; Senz J; Yang W; Spillman MA; Cochrane DR; Shumansky K; Shah SP; Kalloger SE; Huntsman DG
PLoS One; 2013; 8(9):e72162. PubMed ID: 24023729
[TBL] [Abstract][Full Text] [Related]
38. Nuclear G protein-coupled oestrogen receptor (GPR30) predicts poor survival in patients with ovarian cancer.
Zhu CX; Xiong W; Wang ML; Yang J; Shi HJ; Chen HQ; Niu G
J Int Med Res; 2018 Feb; 46(2):723-731. PubMed ID: 29239277
[TBL] [Abstract][Full Text] [Related]
39. Low-Grade Serous Ovarian Cancer: Current Treatment Paradigms and Future Directions.
Grisham RN; Iyer G
Curr Treat Options Oncol; 2018 Sep; 19(11):54. PubMed ID: 30225651
[TBL] [Abstract][Full Text] [Related]
40. The development of high-grade serous carcinoma from atypical proliferative (borderline) serous tumors and low-grade micropapillary serous carcinoma: a morphologic and molecular genetic analysis.
Dehari R; Kurman RJ; Logani S; Shih IeM
Am J Surg Pathol; 2007 Jul; 31(7):1007-12. PubMed ID: 17592266
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
